MedBulletinsAura Celeste
Internal medicine

What's next in internal medicine — November 12, 2026

🎧 Listen to this issueAudio newscast · 4:42 min

This edition gathers four dated milestones expected between November 2026 and the first quarter of 2027: two FDA decisions on cardiometabolic drugs (lorundrostat and CagriSema), a third on a 25 mg presentation of oral semaglutide (Ozempic tablets), and the interim readout of the PREVAIL outcomes trial with obicetrapib. We include only items with a date announced by a regulator or by the company itself, and we flag whether the date is exact or only a quarterly window.

1. Lorundrostat for uncontrolled hypertension

[Pending regulatory decision] [United States] [FDA target action date (PDUFA): December 22, 2026, per Mineralys Therapeutics]
What it is: An oral aldosterone synthase inhibitor proposed for adults with hypertension in combination with other antihypertensives. The application rests on Launch-HTN (phase 3, randomized, double-blind, placebo-controlled, in patients uncontrolled on 2 to 5 drugs; primary endpoint: change in office SBP at 6 weeks vs placebo) and Advance-HTN (phase 2, randomized, double-blind, placebo-controlled; primary endpoint: change in 24-hour ambulatory SBP at 12 weeks vs placebo).
What problem it solves: Resistant hypertension remains common; today the fourth step is usually spironolactone, limited by hyperkalemia and antiandrogenic effects. It would be the second aldosterone synthase inhibitor approved in the US, after baxdrostat (Baxfendy, May 2026).
Critical take: Industry-sponsored and based on a surrogate endpoint (blood pressure), with no cardiovascular event data; potassium and kidney function will need monitoring outside the trial. The PDUFA date is a review target and does not guarantee a decision on that day.

Sources

2. CagriSema (cagrilintide + semaglutide) for obesity

[Pending regulatory decision] [United States] [Estimated date: Q4 2026, per Novo Nordisk]
What it is: A once-weekly combination of an amylin analogue (cagrilintide 2.4 mg) and semaglutide 2.4 mg for weight management. The application was filed on December 18, 2025, based on REDEFINE 1 and REDEFINE 2; on September 21, 2026 Novo Nordisk said it expects the decision in Q4 2026, and in its November 4, 2026 report it said it is preparing for a US launch in early 2027, subject to approval. There is no public PDUFA date.
What problem it solves: Some patients do not reach weight-loss goals on a GLP-1 agonist alone; today the main pharmacologic alternative is tirzepatide.
Critical take: Approval would rest on weight loss, with no completed cardiovascular outcomes trial, and REDEFINE 4 (open-label, 809 patients, 84 weeks) failed to show non-inferiority to tirzepatide 15 mg; the timeline is the sponsor's and may slip.

Sources

3. Oral semaglutide 25 mg for type 2 diabetes

[Pending regulatory decision] [United States] [Estimated date: Q4 2026, per Novo Nordisk]
What it is: Novo Nordisk applied to the FDA for a 25-mg Ozempic tablet for adults with type 2 diabetes. The US label distinguishes Ozempic tablets, with maintenance doses of 4 or 9 mg, from Rybelsus tablets, with doses of 7 or 14 mg; the two are not substitutable on a mg-to-mg basis. The company expects an FDA decision in Q4 2026.
What problem it solves: If approved, the 25 mg dose would widen the oral options for patients who decline injections. Its added benefit on HbA1c and weight will have to be judged on the data supporting approval.
Critical take: It is a dose extension of a known molecule, where gastrointestinal tolerability deserves attention; in our setting its usefulness will depend mainly on price and access.

Sources

4. PREVAIL: obicetrapib and cardiovascular events (interim analysis)

[Ongoing trial] [International] [Estimated date: Q1 2027, per NewAmsterdam Pharma]
What it is: A phase 3, randomized, double-blind outcomes trial of obicetrapib (a CETP inhibitor) vs placebo in more than 9,500 randomized patients with atherosclerotic cardiovascular disease and LDL-C not controlled on maximally tolerated lipid-lowering therapy; the company plans the interim analysis in Q4 2026, with the result expected in Q1 2027. The drug has already been authorized in the European Union (announced September 21, 2026; Ubeslo and, with ezetimibe, Evlarco) for primary hypercholesterolemia or mixed dyslipidemia.
What problem it solves: Many patients miss LDL-C goals on statin plus ezetimibe; today the next step, depending on the patient's profile, is injectable PCSK9 inhibitors or, since July 2026 in the US, oral enlicitide. PREVAIL tests whether obicetrapib reduces cardiovascular events.
Critical take: Several CETP inhibitors (torcetrapib, dalcetrapib, evacetrapib) failed to demonstrate benefit, although REVEAL found fewer major coronary events with anacetrapib. An interim analysis may simply recommend continuing, and lowering LDL-C with this class does not by itself guarantee fewer events.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.